Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells

Prostate

Volumn 63, Issue 2, 2005, Pages 155-168

  Church, Dawn R ^a   Lee, Elyse ^a   Thompson, Todd A ^a   Basu, Hirak S ^a   Ripple, Maureen O ^a   Ariazi, Eric A ^b,c   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cellular growth arrest; Fra 2; JunD

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIBODY; BICALUTAMIDE; BROXURIDINE; CELL DNA; LUCIFERASE; MESSENGER RNA; METRIBOLONE; PROTEIN DERIVATIVE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUND; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DNA DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; GENE VECTOR; GROWTH INHIBITION; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REPORTER GENE; RNA ANALYSIS; TRANSCRIPTION REGULATION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; FOS-RELATED ANTIGEN-2; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 17144365000     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20172     Document Type: Article

References (46)

1. Isaacs JT. Role of androgens in prostatic cancer. Vitam Horm 1994;49:433-502.
2. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995;13:122-129.
3. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-2434.
4. Taplin ME, Ho S-M. Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab 2001;86(8):3467-3477.
5. Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam Horm 1994;49:383-432.
6. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrine Rev 2004;25(2):276-308.
7. Angel P, Karin M. The role of Jun, Fos, and the AP-1 complex in cell-proliferation and transformation. Biochimica Biophys Acta 1991;1072:129-157.
8. Vogt PK, Bos TJ. jun: Oncogene and transcription factor. Adv Cancer Res 1990;55:1-35.
9. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246.
10. Wisdom R. AP-1: One switch for many signals. Exp Cell Res 1999;253:180-185.
11. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and rumorignesis. Oncogene 2001;20:2401-2412.
12. Zerbini LF, Wang Y, Cho J-Y, Libermann TA. Constitutive activation of nuclear factor κB p50/p65 and fra-1 and junD is essential for deregulated interleukin-6 expression in prostate cancer. Cancer Res 2003;63:2206-2215.
13. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89:40-48.
14. Allen RG, Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med 2000;28(3):463-499.
15. Toone WM, Morgan BA, Jones N. Redox control of AP-1-like factors in yeast and beyond. Oncogene 2001;20:2336-2346.
16. Bubulya A, Wise SC, Shen X-Q, Burmeister LA, Shemshedini L. c-Jun can mediate androgen-receptor-induced transactivation. J Biol Chem 1996;271(40):24583-24589.
17. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Cleave ME. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997;272(28):17485-17494.
18. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
19. Partin AW, Rodriguez R. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC, editor-in-chief. Campbell's urology, 8th edn. Philadelphia, PA: Saunders, 2002. pp 1237-1296.
20. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R. Effect of antioxidants on androgen-induced AP-1 and NF-κB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1999;91:1227-1232.
21. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-5386.
22. Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12:941-953.
23. Rago RP, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem 1990;191:31-34.
24. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acid Res 1991;19:2499.
25. Bollag DM, Rozycki MD, Edelstein SJ. Gel electrophoresis under denaturing conditions. In: Protein methods, 2nd edn. New York (NY, USA): Wiley-Liss, Inc; 1996. pp 107-154.
26. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002;277(29):26321-26326.
27. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993;5:1304-1311.
28. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400.
29. Feng Z, Joos HJ, Vallan C, Mühlbauer R, Altermatt HJ, Jaggi R. Apoptosis during castration-induced regression of the prostate is Fos dependent. Oncogene 1998;17:2593-2600.
30. Angel PE, Herrlich PA. Section II. Regulation of AP-1 activity and synthesis. In: Angel PE, Herrlich PA, editors. The FOS and JUN families of transcription factors. Boca Raton (FL, USA): CRC Press, Inc.; 1994. pp 37-39.
31. Okazaki S, Ito T, Ui M, Watanabe T, Yoshimatsu K, Iba H. Two proteins translated by alternative usage of initiation codons in mRNA encoding a JunD transcriptional regulator. Biochem Biophys Res Comm 1998;250:347-353.
32. Lallemand D, Spyrou G, Yaniv M, Pfarr CM. Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting, and stimulated fibroblasts. Oncogene 1997;14:819-830.
33. Yazgan O, Pfarr CM. Differential binding of the menin tumor suppressor protein to JunD isoforms. Cancer Res 2001;61:916-920.
34. Yazgan O, Pfarr CM. Regulation of two JunD isoforms by jun N-terminal kinases. J Biol Chem 2002;277(33):29710-29718.
35. Short JD, Pfarr CM. Translational regulation of the junD messenger RNA. J Biol Chem 2002;277(36):32697-32705.
36. Matsui M, Tokuhara M, Konuma Y, Nomura N, Ishizaki R. Isolation of human fos-related genes and their expression during monocyte-macrophage differentiation. Oncogene 1990;5:249-255.
37. Nishina H, Sato H, Suzuki T, Sato M, Iba H. Isolation and characterization of fra-2, an additional member of the fos gene family. Proc Natl Acad Sci USA 1990;87:3619-3623.
38. Boss V, Roback JD, Young AN, Roback LJ, Vogt Weisenhorn DM, Medina-Flores R, Wainer BH. Nerve growth factor, but not epidermal growth factor, increases fra-2 expression and alters fra-2/junD binding to AP-1 and CREB binding elements in pheochromocytoma (PC12) cells. J Neurosci 2001;21(1):18-26.
39. Foletta VC. Review: Transcription factor AP-1, and the role of Fra-2. Immunol Cell Biol 1996;74:121-133.
40. Andreucci JJ, Grant D, Cox DM, Tomc LK, Prywes R, Goldhamer DJ, Rodrigues N, Bedard P-A, McDermott JC. Composition and function of AP-1 transcription complexes during muscle cell differentiation. J Biol Chem 2002;277(19):16426- 16432.
41. Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M. Mouse junD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 1994;76:747-760.
42. McCabe LR, Banerjee C, Kundu R, Harrison RJ, Dobner PR, Stein JL, Lian JB, Stein GS. Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: Role of fra-2 and junD during differentiation. Endocrinology 1996;137(10):4398-4408.
43. Lasky SR, Iwata K, Rosmarin AG, Caprio DG, Maizel AL. Differential regulation of junD by dihydroxycholecalciferol in human chronic myelogenous leukemia cells. J Biol Chem 1995;270(34):19676-19679.
44. Li L, Liu L, Rao JN, Esmaili A, Strauch ED, Bass BL, Wang J-Y. JunD stabilization results in inhibition of normal intestinal epithelial cell growth through P21 after polyamine depletion. Gastroenterology 2002;123(3):764-779.
45. Gunthert AR, Gundker C, Hollmann K, Emons G. Luteinizing hormone-releasing hormone induces junD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun 2002;294(1):11-15.
46. 2. Prostate 2003;55:159-167.